Does Organon’s 50% Share Price Slide Signal Opportunity in 2025?
-
Wondering if Organon at around $7 a share is a bargain in disguise or a value trap waiting to happen? This article is going to unpack that in plain English so you can decide for yourself.
-
Over the last week the stock has crept up about 1.4%, but that small uptick is set against a much harsher backdrop, with the share price down roughly 52.6% year to date and 50.6% over the past year.
-
That steep slide has coincided with ongoing concerns about patent cliffs in women’s health, investor skepticism about the legacy portfolio it was spun out with, and a broader rotation away from slower growth pharma names. At the same time, management has been leaning into its biosimilars and fertility franchises, trying to convince the market that…
